I3 Venture awards info

Emory is full of fledgling biomedical proto-companies. Some of them are actual corporations with employees, while others are ideas that need a push to get them to that point. Along with the companies highlighted by the Emory Biotech Consulting Club, Dean Sukhatme’s recent announcement of five I3 Venture research awards gives more examples of early stage research projects with commercial potential. This is the third round of the I3 awards; the first two were Wow! Read more

Take heart, Goldilocks -- and get more sleep

Sleeping too little or too much increases the risk of cardiovascular events and death in those with coronary artery disease, according to a new paper from Emory Clinical Cardiovascular Research Institute. Others have observed a similar U-shaped risk curve in the general population, with respect to sleep duration. The new study, published in American Journal of Cardiology, extends the finding to people who were being evaluated for coronary artery disease. Arshed Quyyumi, MD and colleagues analyzed Read more

Repurposing a transplant drug for bone growth

The transplant immunosuppressant drug FK506, also known as tacrolimus or Prograf, can stimulate bone formation in both cell culture and animal Read more

GaBIO

University-industry partnerships: a matter for cautious aggressiveness

Emory President James Wagner was keynote speaker last week at the 2011 Academic & Industry Intersection Conference sponsored by Georgia Bio and the Atlanta Clinical & Translational Science Institute (ACTSI). The conference focused on ethical issues in translating academic research into commercial drugs and medical devices.

Wagner pointed out the great power these relationships hold for the service of humanity, provided they are properly structured and managed. He recommended “cautious aggressiveness” by both universities and industry.

We should incorporate ethical considerations into our partnerships so that the practice of ethics is not “restrictive and paralyzing, but instead becomes part of the design criteria motivating our success, not restricting it.

Wagner is co-chair of President Obama’s Commission for the Study of Bioethical Issues. The commission lists five principles with broad application for biomedical translational research: public beneficence; responsible stewardship; intellectual freedom and responsibility; democratic deliberation; and justice and fairness.

He emphasized that researchers should guard against personal conflicts of interest and ensure against any compromise of research objectivity. But he cautioned against the temptation to value the process of ethics more highly than the ethical principles themselves, and the temptation to substitute compliance for true ethical practice.

Is it possible that we and our partners have come to place too much faith in documented protocols, and that excessive regulatory burden may give investigators a false sense of absolution of their own responsibility to exercise judgment and ethical practice? he asks.

“How does that square with the moral imperative to bring new knowledge that can benefit individuals and society to practice as soon as possible? Wouldn’t it be unethical to withhold the application of such knowledge if it is known to be able to do good?”

Ethical practice should not be an afterthought, Wagner emphasized, but instead a deeply understood and critical part of design and protocol and procedure — where the exercise of expert judgment goes beyond regulatory compliance.

“A challenge to all of our universities is to advance an ethics education that will bring heightened abilities to our investigators and their partners with the goal…of establishing even more trusting partnerships that can bring technology more safely and swiftly…from the minds of creative investigators, to the laboratory bench, to the manufacturing assembly line, to the vendor’s shelves, and to the bedside.”

Posted on by Holly Korschun in Uncategorized 1 Comment